J Mark Cooper

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3835662/publications.pdf

Version: 2024-02-01

80 papers	11,243 citations	44069 48 h-index	69250 77 g-index
81 all docs	81 docs citations	81 times ranked	11675 citing authors

#	Article	IF	Citations
1	Glial activation precedes alpha-synuclein pathology in a mouse model of Parkinsonâ€™s disease. Neuroscience Research, 2021, 170, 330-340.	1.9	23
2	Oral subchronic exposure to the mycotoxin ochratoxin A induces key pathological features of Parkinson's disease in mice six months after the end of the treatment. Food and Chemical Toxicology, 2021, 152, 112164.	3.6	16
3	Impaired Mitophagy and Protein Acetylation Levels in Fibroblasts from Parkinsonâ€™s Disease Patients. Molecular Neurobiology, 2019, 56, 2466-2481.	4.0	50
4	Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology. Molecular Therapy, 2019, 27, 2111-2122.	8.2	120
5	Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain, 2014, 137, 1481-1495.	7.6	258
6	Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Movement Disorders, 2014, 29, 1476-1485.	3.9	384
7	Pramipexole Reduces Phosphorylation of Î±-Synuclein at Serine-129. Journal of Molecular Neuroscience, 2013, 51, 573-580.	2.3	14
8	Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochemistry International, 2013, 62, 1-7.	3.8	166
9	A novel Î±-synuclein missense mutation in Parkinson disease. Neurology, 2013, 80, 1062-1064.	1.1	396
10	G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Human Molecular Genetics, 2012, 21, 4201-4213.	2.9	147
11	Central role and mechanisms of Î²â€cell dysfunction and death in friedreich ataxiaâ€“associated diabetes. Annals of Neurology, 2012, 72, 971-982.	5.3	84
12	Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Annals of Neurology, 2012, 72, 455-463.	5.3	473
13	Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neuroscience Research, 2011, 69, 337-342.	1.9	164
14	Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiology of Disease, 2011, 42, 360-367.	4.4	612
15	Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia. Movement Disorders, 2010, 25, 846-852.	3.9	36
16	Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Human Molecular Genetics, 2010, 19, 4861-4870.	2.9	795
17	Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains. Archives of Neurology, 2010, 67, 1464-72.	4.5	440
18	Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochemistry International, 2010, 57, 525-529.	3.8	35

#	Article	IF	Citations
19	Friedreich's ataxia impact scale: A new measure striving to provide the flexibility required by today's studies. Movement Disorders, 2009, 24, 984-992.	3.9	24
20	Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinsonâ€™s disease pathogenesis. Journal of Neurochemistry, 2009, 110, 1005-1013.	3.9	87
21	Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors. Journal of the Neurological Sciences, 2009, 278, 44-53.	0.6	17
22	Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells. PLoS ONE, 2009, 4, e4756.	2.5	173
23	MELAS mitochondrial DNA mutation A3243G reduces glutamate transport in cybrids cell lines. Experimental Neurology, 2008, 212, 152-156.	4.1	14
24	Friedreichâ€™s ataxia: Coenzyme Q10 and vitamin E therapy. Mitochondrion, 2007, 7, S127-S135.	3.4	50
25	Clinical correlates of mitochondrial function in Huntington's disease muscle. Movement Disorders, 2007, 22, 1715-1721.	3.9	83
26	GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics, 2006, 88, 580-590.	2.9	222
27	Pramipexole protects against MPTP toxicity in non-human primates. Journal of Neurochemistry, 2006, 96, 1315-1321.	3.9	76
28	Coordinating outcomes measurement in ataxia research: Do some widely used generic rating scales tick the boxes?. Movement Disorders, 2006, 21, 1396-1403.	3.9	24
29	Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Annals of Neurology, 2006, 60, 253-255.	5.3	86
30	Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. Journal of Neurochemistry, 2005, 92, 215-215.	3.9	1
31	Human spastin has multiple microtubule-related functions. Journal of Neurochemistry, 2005, 95, 1411-1420.	3.9	54
32	Mutant torsinA, which causes early-onset primary torsion dystonia, is redistributed to membranous structures enriched in vesicular monoamine transporter in cultured human SH-SY5Y cells. Movement Disorders, 2005, 20, 432-440.	3.9	48
33	International cooperative ataxia rating scale (ICARS): Appropriate for studies of Friedreich's ataxia?. Movement Disorders, 2005, 20, 1585-1591.	3.9	68
34	Antioxidant Treatment of Patients With Friedreich Ataxia. Archives of Neurology, 2005, 62, 621.	4.5	211
35	Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. Journal of Neurochemistry, 2004, 91, 1075-1081.	3.9	98
36	Mitochondrial Respiratory Chain Dysfunction in Ageing; Influence of Vitamin E Deficiency. Free Radical Research, 2004, 38, 157-165.	3.3	36

#	Article	IF	Citations
37	Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacology, 2004, 46, 562-569.	4.1	56
38	G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage. Neurochemistry International, 2004, 45, 669-676.	3.8	30
39	Î±-Synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone. Neuroscience Letters, 2003, 351, 29-32.	2.1	53
40	Mitochondrial Dysfunction in Friedreich's Ataxia: From Pathogenesis to Treatment Perspectives. Free Radical Research, 2002, 36, 461-466.	3.3	25
41	Friedreich's ataxia. International Review of Neurobiology, 2002, 53, 147-173.	2.0	7
42	Nitric oxide enhances MPP+inhibition of complex I. FEBS Letters, 2001, 504, 50-52.	2.8	20
43	Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency. Biochemical Journal, 2001, 357, 887.	3.7	16
44	Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency. Biochemical Journal, 2001, 357, 887-892.	3.7	27
45	Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Annals of Neurology, 2001, 49, 590-596.	5.3	246
46	Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Annals of Neurology, 2001, 49, 590-596.	5.3	4
47	Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Human Molecular Genetics, 2000, 9, 2683-2689.	2.9	182
48	Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Human Molecular Genetics, 2000, 9, 275-282.	2.9	312
49	Oxidative-phosphorylation defects in liver of patients with Wilson's disease. Lancet, The, 2000, 356, 469-474.	13.7	130
50	A Missense Mutation of Cytochrome Oxidase Subunit II Causes Defective Assembly and Myopathy. American Journal of Human Genetics, 1999, 65, 1030-1039.	6.2	131
51	Functional consequences of the 3460-bp mitochondrial DNA mutation associated with Leberâ€™s hereditary optic neuropathy. Journal of the Neurological Sciences, 1999, 165, 10-17.	0.6	64
52	Mitochondrial DNA Depletion Syndrome is Expressed in Amniotic Fluid Cell Cultures. American Journal of Pathology, 1999, 155, 67-70.	3.8	48
53	Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. Brain Research, 1998, 809, 12-17.	2.2	102
54	Liver failure associated with mitochondrial DNA depletion. Journal of Hepatology, 1998, 28, 556-563.	3.7	106

#	Article	IF	Citations
55	Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. Journal of the Neurological Sciences, 1998, 158, 24-29.	0.6	147
56	ROTENONE INDUCED MITOSIS, ENDOREDUPLICATION AND APOPTOSIS ARE NOT MEDIATED VIA MITOCHONDRIAL RESPIRATORY CHAIN INHIBITION. Biochemical Society Transactions, 1996, 24, 533S-533S.	3.4	0
57	Antibodies to human optic nerve in Leber's hereditary optic neuropathy. Journal of the Neurological Sciences, 1995, 130, 134-138.	0.6	28
58	The structural organization of the mitochondrial respiratory chain. , 1994, , 1-30.		8
59	Platelet mitochondrial function in Leber's hereditary optic neuropathy. Journal of the Neurological Sciences, 1994, 122, 80-83.	0.6	76
60	Mitochondrial DNA mutation underlying Leigh's syndrome: Clinical, pathological, biochemical, and genetic studies of a patient presenting with progressive myoclonic epilepsy. Journal of the Neurological Sciences, 1994, 121, 57-65.	0.6	49
61	A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease. Journal of the Neurological Sciences, 1994, 125, 77-81.	0.6	64
62	Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. FEBS Letters, 1994, 345, 50-54.	2.8	1,109
63	Biochemical and molecular features of deficiencies of Complexes I, II and III. , 1994, , 75-90.		9
64	Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. Brain Research, 1993, 627, 349-353.	2.2	74
65	Mitochondrial function in Alzheimer's disease. Lancet, The, 1993, 341, 969-970.	13.7	31
66	A new point mutation associated with mitochondrial encephalomyopathy. Human Molecular Genetics, 1993, 2, 2081-2087.	2.9	143
67	Smoking and mitochondrial function: a model for environmental toxins. QJM - Monthly Journal of the Association of Physicians, 1993, 86, 657-660.	0.5	74
68	Mitochondrial function in neurodegeneration and ageing. Mutation Research - DNAging, 1992, 275, 133-143.	3.2	54
69	One-step immunoaffinity purification of complex I subunits from beef heart mitochondria. Protein Expression and Purification, 1992, 3, 223-227.	1.3	4
70	Evidence for intramitochondrial complementation between deleted and normal mitochondrial DNA in some patients with mitochondrial myopathy. Journal of the Neurological Sciences, 1992, 107, 87-92.	0.6	37
71	Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: Effect of ageing. Journal of the Neurological Sciences, 1992, 113, 91-98.	0.6	322
72	Human mitochondrial complex I dysfunction. Biochimica Et Biophysica Acta - Bioenergetics, 1992, 1101, 198-203.	1.0	6

#	Article	IF	Citations
73	Platelet mitochondria function in Parkinson's disease. Annals of Neurology, 1992, 32, 782-788.	5.3	337
74	Mitochondrial function in Parkinson's disease. Annals of Neurology, 1992, 32, S116-S124.	5.3	96
75	Mitochondrial myopathies: clinical defects. Biochemical Society Transactions, 1990, 18, 523-526.	3.4	13
76	Biochemical and molecular aspects of human mitochondrial respiratory chain disorders. Biochemical Society Transactions, 1990, 18, 517-519.	3.4	14
77	Mitochondrial Myopathy with a Defect of Mitochondrial-Protein Transport. New England Journal of Medicine, 1990, 323, 37-42.	27.0	59
78	MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE. Lancet, The, 1989, 333, 1269.	13.7	1,248
79	Molecular defects of NADH-ubiquinone oxidoreductase (Complex I) in mitochondrial diseases. Journal of Bioenergetics and Biomembranes, 1988, 20, 365-382.	2.3	72
80	An animal model of mitochondrial myopathy: A biochemical and physiological investigation of rats treated in vivo with the NADH-CoQ reductase inhibitor, diphenyleneiodonium. Journal of the Neurological Sciences, 1988, 83, 335-347.	0.6	24